Abstracts tagged "gout"

Abstract Number: 0934 • ACR Convergence 2024
Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies
Isak Tengesdal¹, Carlo Marchetti¹, Tim L.Th. Jansen², Marc Y. Donath³, Naomi Schlesinger⁴ and Charles Dinarello¹, ¹University of Colorado, Denver, CO, ²1VieCuri Medisch Centrum, Venlo, Netherlands, ³University of Basel, Basel, Switzerland, ⁴University of Utah, Salt Lake City, UT
Background/Purpose: NLRP3 is emerging as an attractive upstream target of the pathway to down-modulate rather than to completely neutralize IL-1ß levels in both acute and…
Abstract Number: 1096 • ACR Convergence 2024
Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia
Shay Brikman¹, Liel Serfaty, MA², Ran Abuhasira, MD, PhD³, Naomi Schlesinger⁴, Nadav Rappoport⁵ and Amir Bieber⁶, ¹Emek Medical Center, Afula, Israel, ²Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ³Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁴University of Utah, Salt Lake City, UT, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶Emek Medical Center, Clalit Health Services, Raanana, Israel
Background/Purpose: Hyperuricemia (HU) is considered the most important factor preceding Gout. Yet, only a portion of hyperuricemic people develop Gout. Using a machine learning modeling…
Abstract Number: 1992 • ACR Convergence 2024
Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment
Austen herron¹, Miao Ting Lai², Naomi Schlesinger³, Sauer brian⁴, Jorge Rojas⁵, shardool Patel³, Madeline O’Sullivan³, grant Cannon⁶ and Tawnie Braaten³, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, salt lake city, ³University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Seattle VA, Mexico, Mexico, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Immune checkpoint inhibitors (ICIs) produce immune-related adverse events in patients with rheumatic diseases that can often present as a flare of the underlying condition.…
Abstract Number: 2020 • ACR Convergence 2024
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Peter Lipsky¹ and anthony yeo², ¹AMPEL BioSolutions, Charlottesville, VA, ²Independent consultant, Ann arbor, MI
Background/Purpose: Pegloticase is a pegylated recombinant uricase approved for treatment of chronic uncontrolled gout. Because of the development of anti-drug antibodies (ADA), persistent urate lowering…
Abstract Number: 0273 • ACR Convergence 2024
Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study
Elizabeth Lopez¹, Lesley Jackson², Kenneth Saag³ and Maria I. ("Maio") Danila⁴, ¹University of Alabama at Birmingham, Montgomery, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Many people with gout utilize the emergency department (ED) for acute gout care, but many do not receive subsequent adequate outpatient care for long-term…
Abstract Number: 1067 • ACR Convergence 2024
Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
Ali Nasir¹ and Nasir Khan², ¹Trinity Health Grand Rapids/Michigan State University, Grand Rapids, MI, ²Trinity Health Grand Rapids, Grand Rapids, MI
Background/Purpose: Hospitalizations for gout flare have been increasing, doubling between 1993 to 2011 from 4.4 to 8.8 admissions per 100000 adults. Despite this increase, urate-lowering therapy (ULT)…
Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Blanka Stiburkova¹, Aleš Kvasnička², Barbora Pisklakova², Jakub Rozhon², Karel Pavelka³ and David Friedecky², ¹Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ²Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic, ³Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…
Abstract Number: 2005 • ACR Convergence 2024
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
Puja Khanna¹, Vibeke Strand², Atul Singhal³, Herbert Baraf⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Sheldon Leung⁵, Hugues Santin-Janin⁷, Aletta Falk⁸ and Alan Kivitz⁹, ¹University of Michigan, Ann Arbor, MI, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Southwest Arthritis Research Group, Mesquite, TX, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Sobi, Stockholm, Sweden, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: SEL-212 is a once-monthly, investigational, two-component infusion therapy consisting of pegadricase (SEL-037, a pegylated uricase) and immune-tolerizing nanoparticles containing sirolimus (SEL-110), for the treatment…
Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: L15 • ACR Convergence 2023
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Robert Keenan¹, James Cheng-Chung WEI², Sarah Morris³, Pamella Mundell³, Wen Wei³, Ke Shi³, Zancong Shen³, Vijay Hingorani⁴, Shunqi Yan³, Bahram Kiani⁵ and Litain Yeh³, ¹Arthrosi Therapeutics, Inc., Chapel Hill, NC, ²Chung Shan Medical University, Taichung, Taiwan (Republic of China), ³Arthrosi Therapeutics, Inc., San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: AR882 is a novel and selective URAT1 inhibitor currently in clinical stage development for the treatment of gout and tophaceous gout and has demonstrated…
Abstract Number: 0234 • ACR Convergence 2023
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Sara Tedeschi¹, Keigo Hayashi¹, Yuqing Zhang², Hyon K. Choi³ and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: ACR gout treatment guidelines recommend a target serum urate (SU) of < 6 mg/dL and anti-inflammatory flare prophylaxis for at least 3-6 months after…
Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Jie Wei¹, Hyon K. Choi², Nicola Dalbeth³, Xiaoxiao Li⁴, Changjun Li⁵, Chao Zeng⁶, Guanghua Lei⁶ and Yuqing Zhang⁷, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³University of Auckland, Auckland, New Zealand, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁷Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
Abstract Number: 1107 • ACR Convergence 2023
Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
James Mossell¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux² and Sanjay Chabra³, ¹Arthritis and Osteoporosis Center of South Georgia, Tifton, GA, ²Horizon Therapeutics, Deerfield, IL, ³Texas Arthritis Center, El Paso, TX
Background/Purpose: Pegloticase can lower serum urate (SU) in patients with uncontrolled gout who are refractory to/intolerant of oral urate-lowering therapies. However, antidrug antibodies (ADAs) can…
Abstract Number: 1804 • ACR Convergence 2023
Plant-based Diet Quality and the Risk of Gout: Results from Two Prospective Cohort Studies of US Men and Women
Sharan Rai¹, Frank Hu¹, Molin Wang¹, Hyon K. Choi² and Qi Sun¹, ¹Harvard T.H. Chan School of Public Health, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Plant-based diets are growing in popularity due to their health benefits for selected cardiometabolic diseases as well as favorable environmental impact. However, the limited…
Abstract Number: 0236 • ACR Convergence 2023
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
orrin Troum¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹University of Southern California Keck School of Medicine and Providence Saint John's Health Center, Santa Monica, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is associated with high comorbidity, including cardiovascular (CV), metabolic, and renal disease,1 with even higher burden in uncontrolled gout patients (pts).2 CV (myocardial…

« Previous Page
1
…
4
5
6
7
8
…
45
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].